DIRS.INFO The most relevant business & tech news

☆ Trade Tracker: Bill Baruch buys more Apple and Amgen
▼ + stars: | 2024-05-08 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailTrade Tracker: Bill Baruch buys more Apple and AmgenBill Baruch, founder and president at Blue Line Capital, joins CNBC's 'Halftime Report' to discuss his latest trades.

Persons: Bill Baruch Organizations: Apple, Blue Line

☆ Amgen, newer rivals could threaten Novo Nordisk and Eli Lilly's weight loss drug dominance
▼ + stars: | 2024-05-07 | by ( Scott Olson | Getty Images | ) www.cnbc.com time to read: +10 min

Amgen is among the leaders of a pack of drugmakers racing to join the market with their own weight loss treatments. Amgen's drug, MariTide, is taken less frequently than Novo Nordisk's Wegovy and Eli Lilly's Zepbound, and may cause longer-lasting weight loss than the market leaders' injections. Novo Nordisk and Eli Lilly are also working on new weight loss drugs. The competition for a slice of the weight loss market has only grown more fierce in recent months. An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, U.S., December 11, 2023.

Persons: NOVO.B, Scott Olson, Eli Lilly, Nordisk's Wegovy, Eli Lilly's Zepbound, Amgen, William Blair, Matt Phipps, Bob Bradley, Boehringer Ingelheim, Phipps, Zepbound, Chris Schott, MariTide, Mario Tama, he's, Eli Lilly drugs, CagriSema, Eli Lilly’s, Brendan McDermid, Boehringer, Ingelheim, survodutide, Pascal Soriot, Christopher Furlong, dealmaking, David Denton Organizations: New, Halstead Pharmacy, Getty, Novo Nordisk, Nordisk's, William Blair & Company, CNBC, Therapeutics, AstraZeneca, Zealand Pharma, MariTide, Reuters, GLP, Pfizer, Eccogene Locations: Chicago , Illinois, Novo, Amgen, Thousand Oaks , California, New York City, U.S, Zealand, Macclesfield

☆ What's driving this multiday rally, plus Jim Cramer's quick takes on 4 stocks
▼ + stars: | 2024-05-06 | by ( Jeff Marks | ) www.cnbc.com time to read: +4 min

Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. Stock gains continue: The market is higher on Monday, extending its gains over the past three sessions to nearly 3%. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

Persons: Jim Cramer, Jerome Powell, overbought, Jim Cramer's, Jim, Mellody Hobson, Howard Schultz, Laxman Narasimhan, Eli Lilly, Amgen, Lilly, Christian Organizations: CNBC, Stock, Starbucks, Worldwide Developers Conference, VisionPro, Nvidia, pharma, FDA, Simon Property Group, Club, Rockwell Automation, Jim Cramer's Charitable, Apple, Getty Locations: WWDC, Hamburg, Germany

☆ Dr. Gottlieb on Amgen's new weight loss drug: Expect to be on par with Wegovy & Mounjaro or better
▼ + stars: | 2024-05-06 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailDr. Gottlieb on Amgen's new weight loss drug: Expect to be on par with Wegovy & Mounjaro or betterFormer FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss Amgen's new injectable weight loss drugs, how it takes a different approach from other weight loss drugs like Wegovy and Mounjaro, state of the obesity drug market, and more.

Persons: Gottlieb, Scott Gottlieb Organizations: FDA

☆ Generative AI will be designing new drugs all on its own in the near future
▼ + stars: | 2024-05-05 | by ( Trevor Laurence Jockims | ) www.cnbc.com time to read: +12 min

An analogy for understanding the development of AI drugs can be found in the mechanisms of ChatGPT. As a result, it's a drug discovery process that has a 90% failure rate. Some of the noted flaws of generative AI, its propensity to "hallucinate" for example, could prove to be powerful in drug discovery. AI is learning to distinguish drugs from non-drugs, and to create new drugs, in the same way that ChatGPT can create sentences, Ellington said. Now, AI models are helping narrow down the possibilities, so scientists more quickly know the optimal modifications to try.

Persons: ChatGPT, Kimberly Powell, Google's, —, AlphaFold, Powell, Rau, Lilly, Eli Lilly, Diogo Rau, It's, Amgen, Andy Ellington, Ellington, Daniel Diaz, Diaz, We've Organizations: Nvidia, CNBC Technology, Summit, University of Texas, Austin, NVIDIA, biosciences, UT's Institute, Foundations of Machine, Cadence Locations: Nature

☆ Here are Friday's biggest analyst calls: Apple, Target, Coinbase, Berkshire Hathaway, Estee Lauder & more
▼ + stars: | 2024-05-03 | by ( Michael Bloom | ) www.cnbc.com time to read: +6 min

JPMorgan upgrades Williams-Sonoma to neutral from underweight JPMorgan said in its upgrade of the stock that the home furnishings category is stabilizing. "We are downgrading shares of EXPE to Mkt Perform from OP with a target price of $145 vs. $165 previously." JPMorgan upgrades Joby to neutral from underweight JPMorgan said its bear thesis has largely played out for the aviation company. Guggenheim reiterates Target as buy Guggenheim said investors should buy the dip in shares of Target . Morgan Stanley downgrades Estee Lauder to equal weight from overweight Morgan Stanley said it sees a slower recovery for shares of Estee Lauder .

Persons: Stifel, Wells, Truist, OLLI, Guggenheim, Tim Cook, William Blair, Amgen, Jefferies, We've, Ari sta, it's, Morgan Stanley downgrades Estee Lauder, Morgan Stanley, Estee Lauder, TD Cowen, Parsons, Bernstein, Oppenheimer, CFRA, Berkshire Hathaway Organizations: RBC, FTAI Aviation, Pacific, Union Pacific, JPMorgan, Williams, WSM, BMO, Bank of America, Apple, Kiniksa Pharmaceuticals, JOBY, Guggenheim, Target, Citi, MCW, Arista, PSN, Avidity, ~$ Locations: Sonoma, EXPE, GEICO

☆ Here's what's driving Friday's stock action in Apple, Coterra and Eli Lilly
▼ + stars: | 2024-05-03 | by ( Morgan Chittum | ) www.cnbc.com time to read: +2 min

Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. "This is the kind of number you need that basically says the Fed is doing their job," Jim Cramer said. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

Persons: Jim Cramer, Coterra, naysayers, Eli Lilly, drugmaker Amgen, we're, Jim Cramer's, Jim Organizations: CNBC, Club, Apple, Coterra Energy, Mizuho Securities

☆ Amgen soars 16% after it talks up a new weight loss drug that could be injected monthly instead of weekly
▼ + stars: | 2024-05-03 | by ( Matthew Fox | ) www.businessinsider.com time to read: +3 min

The company talked up its experimental GLP-1 weight-loss drug, MariTide. The new weight loss drug could be injected monthly instead of weekly. AdvertisementThe competition is fierce in the GLP-1 weight loss market, with Novo Nordisk's Ozempic and Wegovy and Eli Lilly's Mounjary and Zepbound dominating sales. AdvertisementWhile a monthly weight-loss injected drug may sound appealing to patients, it is likely still far from hitting the market, assuming it passes all of its clinical trials. And even more convenient than a monthly injection of GLP-1 would be a weight loss pill, though Amgen said it ditched development of its oral weight loss drug candidate to instead focus on the development of MariTide.

Persons: —, Amgen, Robert Bradway, Eli Lilly's Mounjary, Bradway, MariTide, James Bradner, Goldman Sachs, it's, hasn't Organizations: Service, Nordisk's Ozempic, Wall Street Locations: America

☆ Stocks making the biggest moves midday: Apple, Expedia, Block, Live Nation and more
▼ + stars: | 2024-05-03 | by ( Hakyung Kim | ) www.cnbc.com time to read: +3 min

Check out the companies making headlines in midday trading: Apple — The tech giant jumped more than 6% after announcing it would repurchase $110 billion in shares . That topped analysts' estimates for earnings of $1.50 per share on revenue of $90.01 billion, per LSEG. Block — The payment services provider added 1% after posting first-quarter results that beat analysts' expectations. Live Nation Entertainment — Shares jumped 9% on the back of better-than-expected first-quarter revenue. However, the company beat analysts' expectations for the first quarter.

Persons: LSEG, Piper Sandler, FactSet, Eli Lilly, Cloudflare, Jefferies, —, Alex Harring, Lisa Kailai Han, Michelle Fox, Pia Singh Organizations: Apple, Management, Wall Street, BMO Capital Markets, Expedia, Holdings, bullish Bank of America, Novo Nordisk, Arista Networks, Arista Locations: Thursday's, billings

☆ Amgen stock soars on weight loss injection progress as Novo Nordisk, Eli Lilly shares slide
▼ + stars: | 2024-05-03 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +4 min

That fueled investor concerns about new competition in the rapidly growing weight loss drug industry, sending shares of the current obesity players, Novo Nordisk and Eli Lilly , lower on Friday. Eli Lilly shares dropped nearly 3%, while Novo Nordisk's U.S.-traded shares fell more than 1%. Still, investors were pleased with Eli Lilly on Tuesday after the company assured them it can overcome ongoing supply constraints for its popular drugs. Eli Lilly hiked its full-year guidance in part due to optimism around increased production of Zepbound, its diabetes injection Mounjaro and similar drugs for the rest of the year. That signals Novo Nordisk is struggling to meet demand for the treatment.

Persons: Amgen, Eli Lilly, Bob Bradway, Bradway, Jay Bradner, autoinjector, Novo Nordisk's Wegovy, Eli Lilly's Zepbound, William Blair, Matt Phipps, Michael Yee, Amgen's Bradway, Karsten Munk Knudsen Organizations: Novo Nordisk, Novo Nordisk's, Jefferies, MariTide, Nordisk Locations: Novo Nordisk's U.S, North Carolina, Indiana, Ireland, Germany, U.S

☆ Stocks making the biggest moves premarket: Apple, Amgen, Cloudflare and more
▼ + stars: | 2024-05-03 | by ( Lisa Kailai Han | ) www.cnbc.com time to read: +3 min

Hershey — Shares of the chocolate confectionary maker added about 1% after Hershey posted a first-quarter earnings beat. Hershey's $3.25 billion revenue also beat the $3.11 billion consensus. Amgen — Shares soared 13% after the biotech firm posted a first-quarter earnings and revenue beat. Cloudflare — The stock continued to sink, plunging 12% after reporting weak full-year guidance, although Cloudflare posted a first-quarter earnings and revenue beat. However, Coinbase's first-quarter revenue of $1.64 billion beat the $1.34 billion consensus, according to LSEG.

Persons: Hershey, LSEG, Apple, Eli Lilly, Cloudflare, Expedia, Piper Sandler, Fortinet, FactSet, Jefferies, Coinbase's, Benjamin Nolan, — CNBC's Brian Evans, Michelle Fox, Hakyung Kim, Tanaya Macheel Organizations: Hershey —, Apple, Novo Nordisk, BMO Capital Markets, Revenue, Arista Networks, Arista, LSEG . Union Pacific, JPMorgan Locations: billings, LSEG, Stifel

Check out the companies making headlines in after-hours trading: Apple — The iPhone maker advanced 7% as it announced a $110 billion share repurchase and a top- and bottom-line beat. That surpassed analysts' estimates for earnings of $1.50 per share on revenue of $90.01 billion, per LSEG. Expedia posted a beat on first-quarter revenue, which came in at $2.89 billion, surpassing analysts' estimates of $2.81 billion, per LSEG. Block reported adjusted earnings of 85 cents per share on revenue of $5.96 billion in the first quarter. Those results beat analysts' estimates for earnings of 72 cents per share and revenue of $5.82 billion, per LSEG.

Persons: Expedia, Amgen, LSEG, Fortinet, Cloudflare, DaVita, FactSet, —, Christina Cheddar, Berk Organizations: Apple Locations: billings

☆ Amgen scraps experimental weight loss pill, moves forward with injection
▼ + stars: | 2024-05-02 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

Amgen on Thursday said it will stop developing its experimental weight loss pill and instead move forward with its injectable drug and other products in development for obesity. Amgen is developing an injectable obesity treatment called MariTide, which is an ongoing mid-stage trial in obese or overweight adults without diabetes. The drugmaker's oral drug, called AMG-786, is the second weight loss pill to be discontinued over the last year. Investors are laser-focused on Amgen's pipeline of experimental weight loss treatments. Amgen's injectable treatment also appears to help patients keep weight off after they stop taking it based on some clinical trial data.

Persons: Amgen, Eli Lilly, Jay Bradner, Novo Nordisk's Wegovy, Eli Lilly's Zepbound, Zepbound Organizations: Novo Nordisk, Pfizer, Novo Nordisk's Locations: Amgen, Thousand Oaks , California, MariTide, Novo

☆ Stock futures rise after Apple reports, traders look to April payrolls data: Live updates
▼ + stars: | 2024-05-02 | by ( Pia Singh | ) www.cnbc.com time to read: +2 min

Futures tied to the Dow Jones Industrial Average gained 212 points, or 0.55%. S&P 500 futures rose nearly 0.3%, while Nasdaq 100 futures advanced about 0.5%. In extended trading, Apple advanced more than 6% after it announced a $110 billion share repurchase and a top -and bottom-line beat. The S&P 500 popped 0.91%, while the Dow gained 0.85%. The S&P 500 is off by 0.7% week to date, while the Nasdaq is down nearly 0.6%.

Persons: Cloudflare, Dow, Jerome Powell, Sonu Varghese, payrolls, Dow Jones Organizations: New York Stock Exchange, Stock, Dow Jones Industrial, Nasdaq, Apple, Biotech Amgen, Dow, Carson Group Locations: New York City, U.S

☆ Stock futures rise after Fed decides to hold rates steady: Live updates
▼ + stars: | 2024-05-01 | by ( Alex Harring | ) www.cnbc.com time to read: +2 min

Stock futures advanced Wednesday night as investors looked ahead to more corporate earnings due Thursday and key labor data set for later in the week. S&P 500 futures climbed 0.3%. Restaurant delivery service DoorDash dropped 15% after reporting a wider loss per share than Wall Street forecast. Those moves followed a choppy day on Wall Street as investors reacted to the Federal Reserve's decision to keep interest rates unchanged. The Dow finished about 0.2% higher, while the S&P 500 and Nasdaq Composite both closed the session lower by roughly 0.3%.

Persons: DoorDash, Jerome Powell, Eric Winograd, Winograd, Coinbase Organizations: Dow Jones Industrial, Nasdaq, Qualcomm, Federal, Dow, Apple, Moderna Locations: AllianceBernstein, Friday's

☆ 12 portfolio companies report earnings in the week ahead. What we want to hear from each
▼ + stars: | 2024-04-27 | by ( Zev Fima | ) www.cnbc.com time to read: +15 min

The action quickly and sharply reversed back to the upside Friday after blowout earnings reports from Alphabet and Microsoft . In the week ahead, earnings are likely to drive the action again, though we'll get a few important macroeconomic reports. Earnings: We've got the biggest week of the earnings season ahead of us, with 12 Club holdings set to report. Eli Lilly 's report Tuesday morning continues to be all about sales of type-2 diabetes treatment Mounjaro and weight-loss drug Zepbound. In DuPont 's report Wednesday morning, we're looking for a continued rebound in its semiconductor business following a sequential increase last quarter.

Persons: Ford, we'll, Dow Jones, We've, Buckle, Eaton, Eli Lilly, Lilly, We're, Estee Lauder, Fabrizio Freda, we've, Linde, Bausch, Royal Philips, Woodward, SIRI, Archer, Johnson, Stanley Black, Decker, BAX, Cardinal Health, Parker, Belden, Jim Cramer's, Jim Cramer, Jim Organizations: Nasdaq, Microsoft, Meta, Google Search, Big Tech, Nvidia, Broadcom, Ford Motor, Honeywell, Danaher, Labor Department, Labor, PMI, Services PMI, GE Healthcare, Amazon Web Services, Starbucks, Deutsche Bank, DuPont, Bausch Health, U.S ., Appeals, Apple, iPhones, Vision, ON Semiconductor, Resource Partners, Franklin Resources, Paramount, Transocean Ltd, Semiconductors, Arch Capital, Logitech International, Lattice Semiconductor, F5 Networks, Sanmina Corporation, GE HealthCare, PayPal, 3M Company, McDonalds, Enterprise Products Partners, Cola Company, Melco Resorts, Entertainment, SiriusXM Holdings, Oatly, American Electric Power Company, Leidos Holdings, Marathon Petroleum, Daniels, Midland Co, Equitrans Midstream Corporation, HSBC Holdings, HSBC, Devices, Caesars Entertainment, Lumen Technologies, Mondelez, Pfizer, CVS Health, Barrick, Mastercard Inc, Cruise Line Holdings Ltd, Kraft Heinz Company, Marriott International, Ares, Generac Holdings, Johnson Controls, Cenovus Energy Inc, Qualcomm, Devon Energy, Paycom, Axcelis Technologies, Coeur D'Alene Mines, Sunnova Energy International, MGM Resorts International, MGM, Solar Inc, Oil, Allstate, Co, Tenable Holdings, Enovix Corporation, Gladstone Capital, Avis Budget Group, eBay, EBAY, LIN, Novo Nordisk, Natural Resources, PENN Entertainment, Apache, ConocoPhillips, InMode Ltd, Baxter International, Cardinal, Regeneron Pharmaceuticals, Apollo Global Management, LLC, Cinemark Inc, Dominion Energy, Coterra Energy, Coinbase, Bill.com Holdings, Booking Holdings, United States Steel, AXT Inc, Materials, Energy, Hershey Company, XPO Logistics, Cboe, American Pipeline, Amneal Pharmaceuticals, Brookfield Business Partners, Brookfield Renewable Corporation, Magna International, Jim Cramer's Charitable, CNBC, Traders, New York Stock Exchange, Bloomberg, Getty Locations: U.S, megaprojects, China, Eaton, Corning, Coeur D'Alene, Albemarle, ALB, Novo, New York

☆ Microsoft shares jump 4% after the big AI winner delivers in all the right places
▼ + stars: | 2024-04-25 | by ( Jim Cramer | ) www.cnbc.com time to read: +9 min

However, momentum from AI services will keep Azure growth stabilized at these high levels, outperforming the market's expectations. AI services continue to be a large source of revenue growth, contributing seven percentage points of growth. The Office Commercial Products and Cloud Services revenue rose 12%, while the Office Consumer Products and Cloud Services revenue grew 4%. Windows Commercial Products and Cloud Services revenue increased 12%, driven by demand for Windows 365. The company guided Azure's constant currency revenue growth to 30% to 31%, which is higher than estimates of 29%.

Persons: OpenAI, Satya Nadella, there's, we're, Jim Cramer's, Jim Cramer, Jim, Satya Narayana Nadella, Lucas Jackson Organizations: Microsoft, Revenue, Google, Fortune, Productivity, Products, Cloud Services, Consumer Products, Novo Nordisk, Nvidia, Activision, Windows, Management, CNBC Locations: OpenAI, ChatGPT, Novo, Manhattan, New York City

☆ A pullback in this biotech stock has created a buying opportunity, according to the charts
▼ + stars: | 2024-04-22 | by ( Katie Stockton | ) www.cnbc.com time to read: +2 min

Amgen has been in pullback mode since the beginning of February, losing roughly 13% within the context of its long-term uptrend. For those interested in "buying the dip," this may be a good time to revisit the stock, noting the decline looks overdone in the short term. There has been a positive reaction from AMGN to a short-term counter-trend "buy" signal from Tom DeMARK's TD Combo model, which supports a minimum two-week bounce. With Friday's reversal bar on AMGN's daily chart, combined with today's strength, our preferred momentum indicator the daily MACD is back on a "buy" signal. The MACD also shows a positive short-term divergence, supporting a bigger relief rally for AMGN in the near term.

Persons: Amgen, Tom DeMARK's Organizations: AMGN

☆ Final Trades: Shell, 2-YR T-Note and Amgen
▼ + stars: | 2024-04-12 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailFinal Trades: Shell, 2-YR T-Note and AmgenThe Investment Committee give you their top stocks to watch for the second half.

Organizations: Shell, Investment

☆ These stocks may have trouble living up to expectations for a big earnings turnaround this year
▼ + stars: | 2024-03-26 | by ( Pia Singh | ) www.cnbc.com time to read: +3 min

This in effect creates an 'implied' 2H of 2024 guidance that is perhaps excessively optimistic," CEO Adam Parker wrote Sunday. Parker's warning comes after S & P 500 reported earnings growth of 4.2% for the fourth quarter on a year-over-year basis, per FactSet. He also screened for stocks in which there's a big difference between earnings expectations for the first and the second half of the year. Parker surmises that these stocks may disappoint on these aggressive earnings turnarounds. Consensus estimates from analysts surveyed by FactSet suggest the stock, which is down nearly 5% this year, could gain 13.2% from Monday's close.

Persons: Adam Parker, Parker, AbbVie, FactSet, Wells Fargo, Estee Lauder Organizations: Research, Abbott Laboratories, Humana, Pharmaceutical, FactSet, Mondelez International, Procter, Gamble Locations: —, China, Monday's

☆ Amgen wants in on the booming weight loss drug market — and it's taking a different approach
▼ + stars: | 2024-03-24 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +9 min

Mario Tama | Getty ImagesAmgen is taking a new approach as it tries to stand out in a crowded field of drugmakers racing to develop the next blockbuster weight loss drug. It's too early to say how competitive Amgen will be in the budding weight loss drug space, which Novo Nordisk and Eli Lilly have so far dominated. Goldman Sachs also projects that between 10 million and 70 million Americans will be taking weight loss drugs by 2028. The sustained weight loss in Amgen's study appears to contrast with results seen in clinical trials on Zepbound and Wegovy. An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, U.S., December 11, 2023.

Persons: Mario Tama, Eli Lilly, Goldman Sachs, Zepbound, Eli Lilly's, Amgen's MartiTide, Caroline Apovian, Apovian, Joe Buglewicz, MariTide, Holly Lofton, Eli Lilly’s, Brendan McDermid, Reuters Amgen's, William Blair, Matt Phipps, Phipps Organizations: Getty, Novo Nordisk, Pfizer, Viking Therapeutics, Therapeutics, Zealand Pharma, Boehringer, Center, Weight Management, Wellness, Brigham, Women's, Washington Post, NYU Langone Health, Reuters, William Blair & Company, CNBC Locations: Thousand Oaks , California, Oaks , California, Novo, New York City, U.S

☆ Tesla is one of the most oversold stocks on the Street and could be due for a rebound
▼ + stars: | 2024-03-15 | by ( Lisa Kailai Han | ) www.cnbc.com time to read: +4 min

It may be time to buy shares of Tesla as a popular metric on Wall Street indicates shares could be ripe for a rebound. Analysts have a consensus hold rating on Tesla, which has a 14-day RSI of 29.4. Tesla shares this week dropped 7% after a Wells Fargo downgrade to underweight from equal weight. Boeing is also on the list of Wall Street's most oversold names. Other oversold names on the list include Amgen and Globe Life .

Persons: Tesla, Dupont De Nemours Organizations: Tesla, Dow Jones, Nasdaq, CNBC, Stock, Analysts, Boeing, LSEG, Southwest Airlines, Life, Targa Resources, Garmin, Waste Management, Devon Energy Locations: China, Wells

☆ One of Wall Street's favorite investment vehicles turns 25 years old
▼ + stars: | 2024-03-10 | by ( Jesse Pound | In Jesse-Pound | ) www.cnbc.com time to read: +4 min

One of Wall Street's favorite investment vehicles turns 25 years old on Sunday, but shows no signs of fading to the background as it ages. One of the main conversation points around the 2023 rally for the QQQ, and the entire U.S. market, is the dominance of just a handful of key stocks. Over the years, many key stocks have left the fund, including former top performers like Nextel Communications and Sun Microsystems, which were bought out. Related plays Competition in the ETF industry for the QQQ has expanded dramatically over the past quarter century, including from other Invesco funds. That fund is less than four years old but has already surpassed $20 billion in total assets.

Persons: Wall, Ryan McCormack, McCormack, Todd Sohn Organizations: Nasdaq, Qs, Microsoft, Intel, Qualcomm, Nvidia, Broadcom, Nextel Communications, Sun Microsystems, Pepsico, Amgen Locations: United States, U.S

☆ These are the most overbought stocks with the market at a record, including General Electric
▼ + stars: | 2024-03-01 | by ( Brian Evans | ) www.cnbc.com time to read: +3 min

The S & P 500 hit a fresh intraday record on Friday, building on what was a stellar February for Wall Street. But some stocks on Wall Street may be getting ahead of themselves, while others that have been under pressure could reverse course. Using our stock screener tool, CNBC Pro searched for the most overbought and oversold stocks on Wall Street, measured by their 14-day relative strength index (RSI). Stocks with a 14-day RSI above 70 are thought to be overbought, indicating that shares could soon experience a downturn. Shares of renewable energy firm Constellation Energy are also among the most overbought stocks on Wall Street, with a 14-day RSI of 85.6.

Persons: Insulet Organizations: Wall, Nasdaq, CNBC Pro, Electric, GE, General, GE Aerospace, Constellation Energy, Constellation, FactSet, Health, Humana, LSEG Locations: Wells Fargo

☆ Here are Friday's biggest analyst calls: Nvidia, Apple, Dell, Netflix, Micron, Broadcom, Eli Lilly, New York Community Bancorp & more
▼ + stars: | 2024-03-01 | by ( Michael Bloom | ) www.cnbc.com time to read: +8 min

"We are initiating coverage of Evolent Health with an Outperform rating and $45 price target." Goldman Sachs downgrades Estee Lauder to neutral from buy Goldman downgraded the stock and said it's under "sizeable pressure." "We are upgrading Annexon (ANNX shares) to Overweight from Neutral and establishing a December 2024 price target of $11." Bank of America reiterates Eli Lilly as buy Bank of America raised its price target on the stock to $1000 per share from $800. "Following 4Q23 earnings we are upgrading GoodRx from Neutral to Overweight and increasing our December 2024 price target from $7 to $10."

Persons: Davidson, Campbell, Morgan Stanley, JD, TD Cowen, Parker, Dell, Goldman Sachs, Goldman, Louise Singlehurst, Tom Ford, Jefferies, Root, AVGO's, Stephens, Vita Coco, COCO, Piper downgrades, Piper, Redburn, Oppenheimer, Daiwa, Morgan Stanley downgrades Flywire, Goldman Sachs downgrades Estee Lauder, Estee Lauder, Dwight, Wells, Eli Lilly, Lilly, D.A Organizations: Apple, Vulcan, Merck, Vertex Pharmaceuticals, Bank of America, Broadcom, York Community Bancorp, Netflix, Micron, Mizuho, MU, Citi, EV, Health, Nvidia, Dwight, Hewlett Packard Enterprises, JPMorgan, biosciences, " Bank of America Locations: York, Davidson, Oshkosh, Minneapolis , MN

Search resuls for: "Amgen"

25 mentions found